急性白血病患者を対象とした感情と症状に焦点を当てたエンゲージメント試験 (EASE)
感情と症状に焦点を当てた関与(EASE):急性白血病患者に対する介入のマルチサイト無作為対照試験
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
調査の概要
詳細な説明
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Harriet Richardson
- 電話番号:613-533-6430
- メール:hrichardson@ctg.queensu.ca
研究連絡先のバックアップ
- 名前:Lois Shepherd
- 電話番号:613-533-6430
- メール:lshepherd@ctg.queensu.ca
研究場所
-
-
New Brunswick
-
Saint John、New Brunswick、カナダ、E2L 4L2
- 募集
- Regional Health Authority B, Zone 2
-
コンタクト:
- Alfonso Rivera Duarte
- 電話番号:506 648-7109
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8V 5C2
- 募集
- Juravinski Cancer Centre at Hamilton Health Sciences
-
コンタクト:
- Alejandro Garcia-Horton
-
Kingston、Ontario、カナダ、K7L 2V7
- 募集
- Kingston Health Sciences Centre
-
コンタクト:
- Annette Hay
- 電話番号:77094 613 533-6430
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- Ottawa Hospital Research Institute
-
コンタクト:
- Pierre Villeneuve
- 電話番号:613
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- University Health Network
-
コンタクト:
- Gary Rodin
- 電話番号:416 946-4504
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Odette Cancer Centre
-
コンタクト:
- Lee Mozessohn
- 電話番号:5847 416 480-5000
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:その他:普段のお手入れ
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
実験的:Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
時間枠:4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SASRQ を使用して、通常のケアと比較して EASE 介入の効果を評価し、外傷性ストレス症状を軽減します
時間枠:8週間、12週間、26週間
|
8週間、12週間、26週間
|
|
|
MSAS を使用して身体症状の重症度を軽減するための通常のケアに対する EASE 介入の効果を評価する
時間枠:8週間、12週間、26週間
|
8週間、12週間、26週間
|
|
|
SASRQ を使用して、ASD の診断としきい値 ASD の診断と一致する基準を満たす参加者の数に対する通常のケアと比較した EASE 介入の効果を評価します。
時間枠:4、8、12、26週
|
4、8、12、26週
|
|
|
(MSAS) によって測定される、がんの身体的症状の数および関連する症状に関連する苦痛に対する、通常のケアと比較した EASE 介入の効果を評価します。
時間枠:4、8、12、26週
|
4、8、12、26週
|
|
|
16項目のFAMCAR-P16を使用して、ケアに対する患者の満足度に対するEASE介入の効果を通常のケアと比較して評価します
時間枠:4、8、12、26週
|
4、8、12、26週
|
|
|
10) EQ-5D-5L は、一般的な健康状態を測定するために使用されるため、EASE 介入の利益と費用を比較する経済評価において、質調整生存年数 (QALY) を計算するために使用できます。
時間枠:4、8、12、26、52週
|
4、8、12、26、52週
|
|
|
治療群間で無増悪生存期間を比較するには
時間枠:1年
|
1年
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
時間枠:4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
時間枠:4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
時間枠:4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
時間枠:4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
時間枠:Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
協力者と研究者
協力者
捜査官
- スタディチェア:Gary Rodin、Princess Margaret Hospital, Canada
- スタディチェア:Camilla Zimmerman、Princess Margaret Hospital, Canada
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- SC26
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。